Workers Compensation
The Australian Pain Society has released its first position statement on pharmacists in pain management. For injury managers, it strengthens the case for pharmacist medication reviews on complex claims.
What has the Australian Pain Society published?
In 2026 the Australian Pain Society (APS) released the first edition of its position statement, The Role of the Pharmacist in the Management of Pain. It is the first time Australia's peak multidisciplinary pain body has formally defined what pharmacists contribute to pain care across primary, secondary and tertiary settings, and advocated for that role to be recognised and standardised within pain management frameworks.
The statement opens by quoting the National Strategic Action Plan for Pain Management: rising numbers of Australians are dying from accidental prescription drug overdose, and there is more that can be done. That framing matters. The APS is not positioning pharmacists as an optional extra. It positions them as part of the safety system for the exact medicine classes the statement names as harm drivers: opioids, gabapentinoids and sedatives.
The full document is available on the Australian Pain Society website.
Why are pharmacists in pain management relevant to injury claims?
Quality use of medicines and medication safety is Australia's 10th National Health Priority, driven by rising accidental harm from medicines. The statement highlights growing polypharmacy, defined as taking 5 or more medicines, and notes that pharmacists are among the most accessible health professionals in Australia, including in regional and rural areas where many injured workers live and prescriber access is thin.
For claims teams the relevance is direct. The medicine classes the APS identifies as the main sources of medication-related harm are the same classes that accumulate on long-tail workers compensation and CTP files. When the peak pain body states that pharmacist involvement improves pain control, reduces medication-related harm and enhances quality of life, that is independent, citable support for building a pharmacist medication review into how complex claims are managed.
What does a pharmacist actually do across the pain journey?
The statement maps pharmacist activity across three core domains: assessment, management and monitoring. In assessment, pharmacists evaluate the type and severity of pain, screen for red flags, and gather the full medicines picture including over-the-counter and complementary products and substance use history. In management, they help select and individualise analgesics against the patient's comorbidities and the regulatory framework, including PBS requirements. In monitoring, they track response to therapy, watch dispensing and real-time prescription monitoring data for early refill requests or multiple prescribers, and recommend dose adjustments, switching, tapering or deprescribing.
Beyond individual care, the statement describes pharmacist leadership of analgesic stewardship programs, support at transitions of care such as hospital discharge, and education covering opioid tapering, withdrawal symptom management and take-home naloxone. It positions pharmacists across every level of the system:
| Setting | Examples in the APS statement |
|---|---|
| Primary care | Community pharmacies, general practice, aged care on-site pharmacists, ACCHOs, home medicines reviews |
| Secondary care | Community outpatient clinics, interdisciplinary pain clinics, community palliative care |
| Tertiary care | Hospital and clinical pharmacists, analgesic stewardship pharmacists, discharge and transition services, persistent pain clinics |
| Research and governance | Academia, Primary Health Networks, government agencies |
How strong is the evidence behind the statement?
The APS grounds its position in published evidence. An umbrella review of systematic reviews found pharmacist-led interventions reduced pain intensity in both acute and chronic pain settings, with standardised mean differences ranging from -0.76 to -0.22, and improved physical functioning. Reported quality of life gains reached standardised mean differences of up to 1.03.
On education and counselling, the statement cites evidence that pharmacist-led interventions reduce medication-related adverse effects, improve patient satisfaction and significantly increase adherence (risk ratio 1.09, 95% CI 1.06 to 1.13), with potential cost savings and reduced hospitalisations. It also cites an Australian randomised trial of pharmacist-partnered opioid tapering before total hip or knee arthroplasty, a model directly relevant to compensable surgical pathways.
Who should be providing these services?
The statement draws a practical line. All pharmacists should be able to assess pain, recommend pharmacological and non-pharmacological options, and refer on when needed. Advanced practice sits on top of that: postgraduate qualifications in pain management, FANZCAP fellowship recognition, credentialing for home medicines reviews and residential medication management reviews through the Pharmaceutical Society of Australia, and public listings of members with pain expertise such as the APS website.
One line in the statement deserves particular attention from scheme audiences: pharmacist pain services are patient-centred and can be delivered independently of the supply of medicines, with clinical consultation, education and risk assessment provided even when no dispensing occurs. That is the independence principle in national policy language: clinical advice separated from the commercial act of supply.
What should injury managers do with this?
- Cite the APS position statement when recommending or requesting a pharmacist medication review on a complex claim. It is current, national and independent.
- Screen files for polypharmacy. Five or more medicines is the threshold the statement works from, and it is common on long-tail claims.
- Treat hospital discharge and other transitions of care as review triggers. The statement identifies these as the highest-risk windows for medication harm.
- Use pharmacist support for opioid tapering plans, including before planned surgery, where the evidence base is growing.
- Check credentials. Ask whether the reviewing pain management pharmacist holds relevant credentialing or advanced practice recognition.
Key Takeaways
- The APS position statement, published in 2026, is the first national definition of the pharmacist's role in pain management.
- It names opioids, gabapentinoids and sedatives as the medicine classes driving harm, the same classes that dominate complex injury claims.
- Evidence cited in the statement shows pharmacist-led interventions reduce pain intensity and improve function, quality of life and adherence.
- Pharmacist pain services can be delivered independently of dispensing, which supports conflict-free review on claims.
- Injury managers can cite the statement when requesting a pharmacist medication review on polypharmacy, opioid and transition-of-care files.
Frequently Asked Questions
What is the APS position statement on pharmacists in pain management?
It is the first edition of the Australian Pain Society's national statement, published in 2026, defining what pharmacists do in pain care across primary, secondary and tertiary settings, from assessment and monitoring through to analgesic stewardship and opioid tapering.
Does pharmacist involvement actually improve pain outcomes?
The statement cites an umbrella review of systematic reviews showing pharmacist-led interventions reduced pain intensity in both acute and chronic pain, improved physical functioning and quality of life, and increased medication adherence.
Why does this matter for workers compensation claims?
Complex claims commonly involve opioids, gabapentinoids, sedatives and polypharmacy, the same medicine classes the APS names as harm drivers. The statement gives injury managers independent, citable support for requesting a pharmacist medication review on those files.
How do I find a pharmacist with recognised pain management expertise?
The statement points to credentialed pharmacists through the Pharmaceutical Society of Australia's Credentialed Pharmacist Directory, FANZCAP fellowship recognition, and public listings such as the Australian Pain Society website.
Primary source: Australian Pain Society, The Role of the Pharmacist in the Management of Pain, Position Statement, 1st edition, 2026.
